A therosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in developed countries. A history of premature coronary heart disease (CHD) among first-degree relatives has been shown in multiple epidemiologic studies to be strongly associated with incident myocardial infarction, coronary death, and stroke. [1] [2] [3] [4] Studies have demonstrated a 2-to 7-fold increase in risk of CHD associated with a positive family history (FHx). 5 Familial clustering of CHD risk factors such as hypertension, smoking, and dyslipidemia is well established. 5, 6 Such clustering may be explained by varying degrees of genetic predisposition as well as shared habits among family members. 5 Interestingly, prior data suggest that the risk factors for ASCVD may have differential effects among those with and without a FHx of premature CHD. For example, comparable risk factor profiles have been associated with increased atherosclerotic disease among those with a FHx. [6] [7] [8] Similarly, the risk reduction associated with certain interventions such as smoking cessation may differ according to the presence of a FHx of CHD. 9, 10 A fundamental component of preventive strategies to reduce cardiovascular risk is to increase physical activity (PA). Higher levels of PA are associated with improvement in all forms of ASCVD, including risk factors, CHD, heart failure, and mortality, 11, 12 and as such, achieving and maintaining adequate levels of PA is endorsed by all major guidelines and societies. 13, 14 Although clustering of behavioral cardiovascular risk factors has been noted in many studies, data have been conflicting regarding levels of PA performed by those with compared to those without a FHx of CHD. 15 Given their higher risk status, it would be important to understand whether individuals with a FHx of premature CHD are more (or less) likely to meet AHA recommended levels of PA than those without a similar FHx. Furthermore, the relative impact of higher levels of PA for ASCVD prevention among those specifically with a FHx of premature CHD compared to those without such a history is currently unknown. Lastly, we pose the question of whether increasing PA levels over time (ie, going from poor levels to recommended levels) could further reduce ASCVD risk compared to those whose PA levels remained poor, and if that differs among those with and without a FHx. We hypothesized that baseline PA levels would be higher among those with a FHx of CHD because persons with FHx may be more likely to adopt healthy lifestyle because of knowledge of their baseline risk. We also hypothesized that a positive FHx of premature CHD would modify the association between PA and incident ASCVD.
Methods

Study Population
The Atherosclerosis Risk in Communities (ARIC) Study is a multicenter, predominantly biracial, prospective cohort of middle-aged men and women from 4 US communities: Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland. The ARIC Study design has been previously reported. 16 Individuals aged 45 to 64 years were enrolled between 1987 and 1989 when they took part in a baseline (visit 1) clinic examination. Participants have taken part in up to 4 additional main visits: 1990-1992 (visit 2), 1993-1995 (visit 3), 1996-1998 (visit 4), and 2011-2013 (visit 5).
Of 15 792 participants evaluated at ARIC visit 1, we excluded those with prevalent CHD (n=766), defined by selfreported prior physician diagnosis of myocardial infarction or coronary revascularization, or prevalent myocardial infarction by 12-lead ECG at visit 1. We also excluded those with prevalent heart failure at visit 1 (n=599), defined by (1) those with an affirmative response to the question: "Were any of the medications you took during the last 2 weeks for heart failure?" or (2) those with stage 3 or "manifest heart failure" as determined by Gothenburg criteria. 17 Participants with prevalent CHD and heart failure were excluded because their underlying health conditions may limit their ability to maximally perform PA, or they may have restrictions placed on their allowed PA intensity/duration as prescribed by their healthcare provider. Additionally, because of small numbers, individuals who were nonblack or nonwhite (n=46), as well as blacks from the Minnesota and Maryland centers (n=49) were not included. We also excluded 2391 participants with missing data on parental history of premature CHD or who answered "don't know" when asked about parental history of premature CHD and 1945 participants with missing data on PA. A total of 9996 individuals were eligible for the present analysis. The Institutional Review Boards at all ARIC study sites and the Coordinating Center approved study protocols, and all participants provided written informed consent at each study visit.
Exposures
The primary exposure of interest was PA at visit 1, with a focus on its relationship with incident ASCVD. A FHx of premature CHD was considered as a possible effect modifier of this association. FHx of premature CHD was assessed at visit 1 by self-report via a questionnaire administered to each ARIC participant. Subjects were asked if they had a parent who had a heart attack occurring in a father before the age 55 or in a mother before age 60. Subjects who answered "yes" were counted as yes ("a positive FHx"), whereas those who said "no" were counted as no FHx of premature CHD. Participants who answered "don't know" were excluded from the analyses.
Sports, leisure, and work PA were assessed via a modified Baecke questionnaire at visit 1 and visit 3. For our study, we used data from the sports questionnaire in which individuals reported participation in up to 4 sports within the previous year, as well as the number of hours per week and months per year spent on each sport. As has been done in prior ARIC studies, 18, 19 
Statistical Analysis
Baseline characteristics of the study population were described using means, medians, and proportions stratified by status of FHx of premature CHD. We used v 2 and ANOVA tests for categorical and continuous variables, in order to assess for differences in demographic, clinical, and laboratory characteristics among the study population. Kaplan-Meier curves were constructed for ASCVD-free survival by FHx groups. We used multivariable-adjusted multinomial logistic regression and linear regression methods to determine whether baseline PA groups and change in PA levels between visit 1 and visit 3 differed by FHx of premature CHD status. We then used multivariable-adjusted Cox proportional hazard models to evaluate the associations of PA at visit 1 with incident ASCVD events stratified by FHx of premature CHD status. PA was modeled according to AHA categories, as quartiles, and continuous (90th compared to 10th percentile). All analyses were progressively adjusted as follows: Model 1 included demographics of age, sex, and race/center. Model 2 included the variables from Model 1 as well as possible confounding lifestyle factors of education, BMI, smoking status, and current alcohol intake. Model 2 was considered our primary model. We also examined a third model that included the variables from Model 2 as well as possible mediators of the association of PA and ASCVD including systolic blood pressure, antihypertensive use, diabetes mellitus, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, use of lipid-lowering medications, and estimated glomerular filtration rate.
We tested for whether there was a multiplicative interaction between PA and FHx of premature CHD for incident ASCVD using Wald Tests, with adjustment for Model 2 covariates.
Additionally, to investigate for a possible dose-response relationship, in analyses stratified by FHx of premature CHD, we modeled the continuous association of PA in METS9min/ week with risk of incident ASCVD using restricted cubic splines with knots at 5th, 35th, 65th, and 95th percentiles, adjusted for the factors in Model 2.
Finally, using the same progressively adjusted regression models as above, we assessed the risk of incident ASCVD for change in PA category from visit 1 to visit 3, stratified by FHx of premature CHD status. For this analysis, we excluded 263 participants who developed ASCVD before or on visit 3.
Results
Characteristics of the study population among individuals with and without a FHx of premature CHD are presented in Table 1 . Of 9996 ARIC participants included in the study, 990 (9.9%) reported a FHx for premature CHD. The mean age of the study population was 54AE6 years, 56% were women and 21% of black race. Compared to those without a FHx of premature CHD, participants with a known FHx of premature CHD were slightly younger, had higher levels of total and lowdensity lipoprotein cholesterol and higher triglycerides, and were more likely to be current smokers.
Participants with and without a FHx of premature CHD reported similar levels of PA at baseline visit 1 (423 versus 409 MET9min/week, respectively, P=0.852), and %40% of both groups met AHA recommended PA levels. In multivariable-adjusted models, individuals with a FHx of premature CHD were not more likely to engage in intermediate (odds ratio 0.94 [95% CI 0.79, 1.12], Model 2) or recommended (Table 2) . Over a mean follow-up of 20.9 years, there were a total of 1545 ASCVD events within the group without a FHx of CHD (incidence rate: 8.2 per 1000 person-years), and 178 ASCVD events among individuals with a positive parental history of premature CHD (incidence rate: 8.7 per 1000 person-years). The time to 90% event-free survival was 14.7 years for those without a FHx and 13.8 years for those with a FHx (Figure 1 ).
In the overall cohort, after adjustment for demographics and lifestyle factors, meeting AHA-recommended levels of PA, versus poor levels of PA, was associated with lower risk of incident ASCVD (hazard ratio (HR) 0.84 [0.74, 0.94], Model 2), which remained statistically significant after further adjustment for ASCVD risk factors that may possibly mediate this (Table 4) . Finally, when comparing the 90th to the 10th percentile of PA levels, the benefit conferred by high PA for ASCVD was modestly stronger among those with a FHx (0.76 [0.51, 1.12], Model 2) compared to those without a FHx (0.83 [0.73, 0.94]) but confidence intervals were wide and overlapping for those with a FHx and no significant interaction by FHx status was found (P-interaction=0.533).
Similar patterns were observed when considering a FHx of any CHD (regardless of whether premature or not), with no significant interactions by FHx status (Table 5) .
We also modeled PA as a continuous variable measured in METS9min/week. Using restricted cubic spline models, we found a graded association of higher levels of PA and lower ASCVD risk in those without a FHx of premature CHD (Figure 2A ). Among those with a FHx of premature CHD the confidence intervals are wide, making interpretation difficult ( Figure 2B ).
When assessing changes in AHA categories of PA from visit 1 to visit 3 in the overall cohort, we found that the majority of study participants, 54%, maintained the same levels of PA from visit 1 to visit 3. Over this 6-year period, 22% of the participants decreased, and 24% increased their levels of PA. In multivariable-adjusted analyses, there was no significant difference in the change in PA levels from visit 1 to visit 3 among those with a FHx of premature CHD compared to those without such a history (Table 2 ). Compared to those whose PA levels remained poor, we observed that maintaining recommended levels of PA or increasing levels of PA over time are associated with lower risk of incident ASCVD in both individuals with and without a FHx of premature CHD (P-interaction=0.678) ( Table 6 ).
Discussion
In this analysis of a large cohort of black and white middleaged men and women free of ASCVD or heart failure at Reference (1) Reference (1) Reference (1) 286/1407
10.1
Reference (1) Reference (1) Reference (1 Reference (1) Reference (1) Reference (1) 275/1383 9.7
Reference (1) Reference (1) Reference ( baseline, we found that less than half of the study participants engaged in AHA-recommended levels of PA. Individuals with a positive FHx of premature CHD had higher levels of total and low-density lipoprotein cholesterol and higher triglycerides, but had similarly low levels of PA both at baseline and at a 6-year follow-up compared to those without a positive FHx of premature CHD. Our findings confirm prior studies that higher levels of PA are associated with lower incidence ASCVD, and we now suggest that this association could be similar among individuals with and without a FHx of premature CHD, although more definitive conclusions are limited by the small number of individuals in the former group. Our study findings corroborate recent data that greater than 50% of the American population perform less than the recommended levels of PA 23 and that %250 000 annual deaths can be attributed to the consequences of physical inactivity. 24 The AHA considers meeting recommended levels of PA as one of the metrics with the greatest potential for improvement, 14 and our study further highlights the importance of increasing PA for ASCVD risk prevention. In our study, despite having more adverse lipid profiles and being at an increased risk for ASCVD, only 40% of participants with a FHx of premature CHD performed recommended levels of PA. Such findings emphasize the importance of assessing PA levels at every patient encounter and increasing efforts to counsel patients on the benefits of exercise.
To our knowledge, this is the first study to evaluate the impact of higher levels of PA among individuals with a FHx of premature CHD compared to those without. No interaction was found between higher levels of PA and a FHx of premature CHD. However, despite the lack of statistical significance among the group with a FHx of premature CHD, both groups had similar magnitude of decrease in the risk of ASCVD events. The lack of statistical significance within the group with a FHx of premature CHD is likely explained by the small number of individuals in that group leading to reduced power to detect a significant difference.
FHx of premature CHD has been associated with a significantly increased risk of ASCVD events, 25 and prior studies have indicated that these individuals are more susceptible to the deleterious effects of certain behaviors such as smoking. 9 Screening for FHx of premature CHD is an effective way of identifying a high-risk group that may benefit from receiving more intensive preventative interventions. 26 Tailored counseling of high-risk individuals identified through family risk assessment has been shown to increase healthy behaviors such as consumption of fruits and vegetables, and performing PA for 30 minutes 5 to 6 times a week. 27 Our study demonstrates the high prevalence of modifiable behavior within this high-risk population and suggests a potential benefit with targeted approaches that would lead to increases in PA levels. In our study, %10% of the population reported a parental history of premature CHD. In contrast to other studies, the crude (unadjusted) incidence rates of ASCVD events was not much higher among this subgroup when compared to individuals without such FHx, with only a small difference in time to first event on average. Although simple definitions of FHx have been shown to be associated with ASCVD risk, not everyone has the same family structure, or knowledge of their Figure 2 . Adjusted* restricted cubic spline model showing the hazard ratios (95% CI) for the association of physical activity levels at visit 1 (METS9min/week) and incident ASCVD events, stratified for those without (A) and with (B) a FHx of premature CHD. The solid line represents the hazard ratios and the dashed lines represent the 95% CIs. Knots at 5th, 35th, 65th, and 95th percentiles. Spline centered at score 0. Histogram shows the distribution of METS score. Restricted cubic spline truncated at 1st and 99th percentile of METS score. *Model is adjusted for age, sex, race/center, education, BMI, smoking status, and alcohol intake. ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart disease; FHx, family history; METS, metabolic equivalents of task. Table 6 . Hazard Ratios and 95% CI for Incident ASCVD for Change in AHA-Defined PA Categories From ARIC Visit 1 (1987 Visit 1 ( -1989 to Visit 3 (1993 Visit 3 ( -1995 Reference (1) Reference (1) 39/200 13.4 Reference (1) Reference (1) Reference ( family members' health status. FHx of premature CHD was ascertained at ARIC visit 1 (1987-1989) ; during this time period, there might have been less emphasis on the importance of FHx compared to the present, and perhaps participants were less knowledgeable about their FHx status, potentially leading to misclassification of study participants. A FHx of premature CHD in a sibling may be a stronger risk for ASCVD compared to a parental FHx. 28 Furthermore, a more comprehensive approach called "family risk scores," which compare observed and expected number of relatives with ASCVD in a family compared to population estimates of age/sex disease rates, may further improve risk stratification and allow for inclusion of second-and even third-degree relatives into risk estimates. 3, 29 These data were not available in the overall ARIC cohort. Finally, the relative risks associated with a FHx of premature CHD tend to be largest for people in middle age; the mean age of our study population at baseline was 54 years, so by the end of follow-up, the mean age of the cohort is in their mid-70s. Thus, the relative difference that the presence of a positive FHx confers on incident ASCVD rates would likely be more pronounced in a younger cohort. Our study has some limitations. As with all observational studies, there is the potential for residual confounding. PA was assessed via a questionnaire with the potential for reporting bias. Directly measured fitness correlates better with cardiometabolic risk factors 30 Finally, we were limited by the small number of individuals in the group with a parental history of premature CHD, which decreased the power to detect statistically significant differences. Since the lack of interaction by FHx status was actually contrary to our original a priori hypotheses, we performed a post-hoc power calculation. We determined that our study had adequate power to detect moderate to large differences in the associations between participants with and without a FHx of CHD, although it had limited power to detect small differences. For instance, in the fully adjusted models, we had %92% power to detect hazard ratios twice as large in one FHx group compared to the other, but only 50% power to detect hazard ratios 1.5 times as large.
Despite these limitations, our study has many strengths. ARIC is a well-characterized bi-ethnic cohort of middle-aged individuals, with long-term (21-year) follow-up, and ASCVD events adjudicated by an expert panel. Another strength of the study is the assessment of PA at 2 points in time, over a 6-year period to evaluate change in PA levels by FHx status.
In summary, our study demonstrated that despite more adverse lipid profiles, individuals with a FHx of premature CHD had similar PA patterns as compared to a lower-risk group without such FHx, with less than half meeting AHA recommended levels. PA was associated with a lower risk for incident ASCVD in those without a FHx, and a similar trend was observed within the smaller group of participants with a FHx of premature CHD. These findings have significant clinical implications for strategies to prevent ASCVD in the general population, as well as within this high-risk subgroup. Promotion of PA should be encouraged for all regardless of FHx status. Better strategies for increasing PA levels in the general population as well as in high-risk subgroups are needed. Better ascertainment of FHx (such as using a validated FHx or Family Risk Scores) and of PA (such as using objectively measured PA and/or measured fitness) will enhance the quality of future studies in this field.
